HUE058328T2 - Õssejtterápia endometriális patológiás állapotokban - Google Patents

Õssejtterápia endometriális patológiás állapotokban

Info

Publication number
HUE058328T2
HUE058328T2 HUE19169309A HUE19169309A HUE058328T2 HU E058328 T2 HUE058328 T2 HU E058328T2 HU E19169309 A HUE19169309 A HU E19169309A HU E19169309 A HUE19169309 A HU E19169309A HU E058328 T2 HUE058328 T2 HU E058328T2
Authority
HU
Hungary
Prior art keywords
stem cell
cell therapy
endometrial
pathologies
endometrial pathologies
Prior art date
Application number
HUE19169309A
Other languages
English (en)
Inventor
Carlos Simon
Javier Santamaria
Antonio Pellicer
Irene Cervello
Original Assignee
Asherman Therapy S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asherman Therapy S L filed Critical Asherman Therapy S L
Publication of HUE058328T2 publication Critical patent/HUE058328T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
HUE19169309A 2014-06-17 2015-06-05 Õssejtterápia endometriális patológiás állapotokban HUE058328T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17

Publications (1)

Publication Number Publication Date
HUE058328T2 true HUE058328T2 (hu) 2022-07-28

Family

ID=54329860

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15781411 HUE044823T2 (hu) 2014-06-17 2015-06-05 Õssejtterápia méhnyálkahártya-patológiákban
HUE19169309A HUE058328T2 (hu) 2014-06-17 2015-06-05 Õssejtterápia endometriális patológiás állapotokban

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE15781411 HUE044823T2 (hu) 2014-06-17 2015-06-05 Õssejtterápia méhnyálkahártya-patológiákban

Country Status (21)

Country Link
US (1) US11129851B2 (hu)
EP (3) EP4012023B1 (hu)
JP (2) JP6920062B2 (hu)
CN (2) CN116747241A (hu)
AU (1) AU2015275798B2 (hu)
BR (1) BR112016029558A2 (hu)
CA (1) CA2952559C (hu)
CY (2) CY1122615T1 (hu)
DK (2) DK3569697T3 (hu)
ES (2) ES2736117T3 (hu)
HR (2) HRP20220419T1 (hu)
HU (2) HUE044823T2 (hu)
LT (2) LT3569697T (hu)
MX (1) MX2016016756A (hu)
PL (2) PL3569697T3 (hu)
PT (2) PT3158057T (hu)
RS (2) RS63093B1 (hu)
RU (1) RU2725006C2 (hu)
SI (2) SI3569697T1 (hu)
TR (1) TR201910410T4 (hu)
WO (1) WO2015193737A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013182912A2 (en) 2012-06-06 2013-12-12 Fundacio Privada Institut De Recerca Biomedica Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
SI3569697T1 (sl) 2014-06-17 2022-05-31 Asherman Therapy, S.L. Terapija z matičnimi celicami pri patologijah endometrija
KR20190029587A (ko) * 2016-06-23 2019-03-20 티톤 바이오테크, 인크. 부갑상선 호르몬 1 수용체를 발현하는 세포 및 그의 용도
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
KR20230015832A (ko) 2021-07-23 2023-01-31 차의과학대학교 산학협력단 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0473612B1 (en) 1989-05-05 1996-07-31 Northern Sydney Area Health Service Fertility enhancement
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
CA2400065A1 (en) 2000-03-08 2001-09-13 Harvey J. Kliman Methods of diagnosing and monitoring endometrial glandular development
WO2001089548A2 (en) 2000-05-24 2001-11-29 Schering Aktiengesellschaft Pharmaceutical use of fibulin-1
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
WO2004061074A2 (en) 2002-05-14 2004-07-22 The Board Of Trustees Of The Leland Stanford Junior University Endometrial genes in endometrial disorders
AU2003255355A1 (en) 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20060292567A1 (en) 2002-12-21 2006-12-28 Universitat Leipzig Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs
EP1660228A1 (en) 2003-08-21 2006-05-31 PamGene B.V. Microarray support for bioprobe synthesis
EP1670902A4 (en) 2003-09-08 2008-05-07 Univ Texas METHOD AND COMPOSITION FOR ENHANCING IN VITRO EMBRYONIC DEVELOPMENT BY ENRICHING A CULTURE MEDIUM COMPRISING PROSTAGLANDIN OR PROSTAGLANDIN ANALOGUE
CN1863905A (zh) 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
EP1711618B1 (en) 2003-12-23 2010-08-04 Mount Sinai Hospital Corporation Methods for detecting markers associated with endometrial disease or phase
WO2005117979A2 (en) 2004-05-28 2005-12-15 Applied Research Systems Ars Holding N.V. Use of il-17 in the treatment of fertility-related disorders
RU2434645C2 (ru) * 2006-03-31 2011-11-27 Конинклейке Филипс Электроникс, Н.В. Системы и методы измерения клеток, использующие ультракороткую т2*-релаксометрию
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
US9453259B2 (en) 2011-10-21 2016-09-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation
AU2012346594B2 (en) 2011-11-30 2017-12-21 Agency For Science, Technology And Research GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring
EP2867670B1 (en) 2012-06-27 2018-05-30 Roche Diagnostics GmbH MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
CN106662589B (zh) 2014-03-21 2019-07-30 艾基诺米公司 先兆子痫的早期检测
SI3569697T1 (sl) 2014-06-17 2022-05-31 Asherman Therapy, S.L. Terapija z matičnimi celicami pri patologijah endometrija

Also Published As

Publication number Publication date
LT3569697T (lt) 2022-04-25
EP3569697B8 (en) 2022-04-27
LT3158057T (lt) 2019-09-25
RS59210B1 (sr) 2019-10-31
EP3158057A1 (en) 2017-04-26
CN107073040A (zh) 2017-08-18
ES2910306T3 (es) 2022-05-12
SI3158057T1 (sl) 2019-10-30
EP3158057B1 (en) 2019-04-17
WO2015193737A1 (en) 2015-12-23
PT3158057T (pt) 2019-07-19
EP3569697B1 (en) 2022-01-05
CY1122615T1 (el) 2021-03-12
DK3569697T3 (da) 2022-04-04
CN116747241A (zh) 2023-09-15
JP2020138984A (ja) 2020-09-03
JP2017522288A (ja) 2017-08-10
EP4012023B1 (en) 2024-05-15
US20170128492A1 (en) 2017-05-11
ES2736117T3 (es) 2019-12-26
JP6920062B2 (ja) 2021-08-18
CA2952559A1 (en) 2015-12-23
US11129851B2 (en) 2021-09-28
EP3569697A1 (en) 2019-11-20
DK3158057T3 (da) 2019-07-29
MX2016016756A (es) 2017-11-02
HRP20220419T1 (hr) 2022-05-27
RU2017101147A3 (hu) 2019-02-06
RU2017101147A (ru) 2018-07-17
HRP20191240T1 (hr) 2019-11-01
HUE044823T2 (hu) 2019-11-28
PL3569697T3 (pl) 2022-07-04
SI3569697T1 (sl) 2022-05-31
EP4012023A1 (en) 2022-06-15
AU2015275798B2 (en) 2021-03-25
CA2952559C (en) 2023-01-24
CY1125938T1 (el) 2024-02-16
TR201910410T4 (tr) 2019-08-21
RS63093B1 (sr) 2022-04-29
PL3158057T3 (pl) 2020-05-18
PT3569697T (pt) 2022-05-02
BR112016029558A2 (pt) 2017-08-22
RU2725006C2 (ru) 2020-06-29
AU2015275798A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
LT3158057T (lt) Endometriumo patologijų terapija su kamieninėmis ląstelėmis
HK1231632A1 (zh) 電池
SG11201610831PA (en) Lithium-sulphur battery
PL3134724T3 (pl) Komórka elektrochemiczna
SG10202004286UA (en) Integrated single cell sequencing
PL3157504T3 (pl) Kompozycje stymulujące komórki macierzyste
SG11201607925SA (en) Improved stem cell composition
GB201411985D0 (en) Battery
HUE042287T2 (hu) Lítium-kén cella
SG10201403640XA (en) Stem cells
GB201416493D0 (en) Polypeptides for use in therapy
GB201406700D0 (en) Cervix cells
ZA201505928B (en) Built in gas-fired braii unit
GB201416750D0 (en) Cell preparation
GB201411798D0 (en) Electrochemical cell
GB201406606D0 (en) Improvements in transformer design
GB201410934D0 (en) T cell